DIANA Biotechnologies

Respiratory PCR Panel

Parallel detection of SARS-CoV-2, Influenza A & B, RSV

SARS-CoV-2 Diagnostic Kits

More than 6 million tests performed

Introducing DIANA Biotechnologies

Who we are?

Founded in 2018 with a private investment of ~ 4M EUR

Development of DIANA technology –"the Best Czech Innovation in 2017"

The biggest producer of PCR diagnostics in the Czech Republic

100 employees, top scientists & developers (Biology, Chemistry, IT and Automation)

Global ambitions with globally unique biotech products

Our 4 main business segments

PCR diagnostics

Development and production of innovative PCR diagnostics (incl. direct PCR technology)
Ladership in PCR testing of COVID-19 and other respiratory viruses
In-house bioinformatics, enzyme development, oligo synthesis

Drug discovery & development

Early drug discovery platform: assay development, HST screening, selectivity profiling, ADME testing
CRO services for pharma industry
In-house programs in virology and oncology

Monoclonal antibodies development

Unique pipeline for development of high-affinity monoclonal antibodies
Protein, peptide and small molecular targets, both diagnostic and therapeutic applications

Diagnostic methods development

DIANA technology-based methods for ultra-sensitive detection of biomarkers
Assay development for biotech industry

Integrated manufacturer of high-quality PCR diagnostics

Product portfolio

DBdirect technology (direct PCR, incl. saliva tests)

Multiplex PCR panels for respiratory viruses (4 tests in 1, varianty tracking)

Collection sets for saliva (Lab plastic manufacturing)

Extensions for lab automation (consumables for automation)

Extensive development pipeline for other pathogens, matrices and applications, (incl. allelic discrimination, somatic mutations)

R&D / production capabilities

RNA isolation chemistry (incl. microparticles)

PCR mix chemistry (incl. direct PCR)

RT-PCR enzymes and proteins (novel robust enzyme variants)

Oligonucleotide and probe synthesis

Bioinformatic analysis (unique primer design)

Regulatory expertise (CE-IVD, IVDR compliant)

Advanced application support

Expert support during implementation in clinical lab

Protocols for automation of sample processing (Agilent Bravo)

Data analysis toots for PCR result interpretation

Supporting data processing flow in clinical lab

Recommendation of required equipment (third party / open system)

The largest producer of COVID-19 PCR tests in Czechia

~40 % market share in COVID-19 PCR tests in Czechia

0 +

milion PCR tests from saliva

0 +

milion PCR tests already delivered

0 +

clinical labs in Czechia and Slovakia
(public + private)

0 +

thousands PCR tests per day at the peak of outbeak

1st to screen for COVID variants (alpha, delta, omicron) in Czechia

In-house development and manufacturing patented direct PCR technology

Media coverage

Few in the Czech Republic have stood up for the pandemic as the scientists from DIANA Biotechnologies, winners of the EY Entrepreneur of the Year for the Central Bohemian Region. They accelerated the work of the laboratories, made life easier for us tested and by all this they gained big money for the development of their other projects.

In 2020, DIANA Biotechnologies entered the PCR diagnostics market and developed and launched highly sensitive PCR tests for covid-19 from saliva in record time. This diagnostic is unique worldwide and has a patent application pending in the USA.

Martin Dienstbier and Václav Navrátil of DIANA Biotechnologies, s.r.o. won the EY Start-up Entrepreneur Of The Year 2021 trophy.